Spatial Distribution Of Cd8+And Foxp3+In A Window Of Opportunity For Durvalumab (Medi4736) Plus Metformin Trial In Squamous Cell Carcinoma Of The Head And Neck (Hnscc)

Anti-PD-L1 Immune checkpoint inhibition shows promise. Durvalumab (D) is an anti-PD-L1 monoclonal antibody with effect in solid tumors. Metformin (M) alters immunity in the tumor microenvironment, but clinical benefit has yet to demonstrated. Multiplex immune profiling has shown utility in predicting outcomes in HNSCC. We examine the distribution of CD8+ and FoxP3+ tumor-infiltrating T-cells and digital spatial genomic profiling (DSP) in response to therapy with D ± M.